|Bid||133.45 x 900|
|Ask||133.49 x 1000|
|Day's range||130.09 - 135.60|
|52-week range||76.59 - 331.68|
|Beta (5Y monthly)||1.59|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||264.20|
If you had invested in Novavax (NASDAQ: NVAX) at the beginning of 2020, you'd be sitting pretty right now. Novavax's efforts to develop and market a vaccine for COVID-19 explain the company's terrific performance of late. The company's average price target of $264.20 implies gains of 93% from its share price of $136.86 as of this writing.
Taylor Carmichael (Novavax): Novavax's COVID-19 vaccine is still not on the market anywhere, which has made the stock a real wild ride for investors. The vaccine specialist started off 2020 so small it almost qualified as a micro-cap, with its stock priced at $4 a share. When COVID-19 hit, however, the stock took off.
LOS ANGELES, October 25, 2021--The Law Offices of Frank R. Cruz Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors